Evidence map›Paper›PMID 27241045›Full record

ArticleScientific reports2016

Plasma β-amyloid in Alzheimer's disease and vascular disease.

Shorena Janelidze, Erik Stomrud, Sebastian Palmqvist, Henrik Zetterberg, Danielle van Westen, Andreas Jeromin, Linan Song, David Hanlon, Cristina A Tan Hehir, David Baker and 2 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01208675 (The Swedish BioFINDER Study), which is not on this map. Cited by 369 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
369citing papers in PubMed, 6 pooled it
25.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01208675 completednot on this map

The Swedish BioFINDER Study: Early Diagnosis of Alzheimer's Disease - a Multidisciplinary Approach

TypeobservationalSponsorSkane University HospitalRan2010 to 2024Enrolled1,150ConditionsMild Cognitive Impairment, Alzheimer's Disease, Dementia With Lewy Bodies, Vascular Dementia
3 · Its place in the literature

Who cites it

369 citing papers in PubMed, 6 syntheses or guidelines pooled it, 601 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Results and insights from a phase I clinical trial of Lomecel-B for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Trial
  9. The Effects ofNutrients · 2022
    Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Diabetes, hyperglycemia, and ATN blood biomarkers in Hispanic/Latino populations: SOL-INCA study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  17. Review
  18. Review
  19. Article
  20. Article

309 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

Shorena JanelidzeClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Erik StomrudClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Sebastian PalmqvistClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Henrik ZetterbergClinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Danielle van WestenDepartment of Clinical Sciences Lund, Diagnostic radiology, Lund University, Lund, Sweden.
Andreas JerominQuanterix Corporation, 113 Hartwell Avenue, Lexington, MA, USA.
Linan SongQuanterix Corporation, 113 Hartwell Avenue, Lexington, MA, USA.
David HanlonQuanterix Corporation, 113 Hartwell Avenue, Lexington, MA, USA.
Cristina A Tan HehirDiagnostics and Life Sciences, GE Global Research, Niskayuna, NY, USA.
David BakerJanssen R&D, Titusville, NJ, USA.
Kaj BlennowClinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Skåne University Hospital · SEQuanterix (United States) · USGE Global Research (United States) · USJanssen (United States) · USLund University · SENational Hospital for Neurology and Neurosurgery · GBUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Implementation of amyloid biomarkers in clinical practice would be accelerated if such biomarkers could be measured in blood. We analyzed plasma levels of Aβ42 and Aβ40 in a cohort of 719 individuals (the Swedish BioFINDER study), including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), Alzheimer's disease (AD) dementia and cognitively healthy elderly, using a ultrasensitive immunoassay (Simoa platform). There were weak positive correlations between plasma and cerebrospinal fluid (CSF) levels for both Aβ42 and Aβ40, and negative correlations between plasma Aβ42 and neocortical amyloid deposition (measured with PET). Plasma levels of Aβ42 and Aβ40 were reduced in AD dementia compared with all other diagnostic groups. However, during the preclinical or prodromal AD stages (i.e. in amyloid positive controls, SCD and MCI) plasma concentration of Aβ42 was just moderately decreased whereas Aβ40 levels were unchanged. Higher plasma (but not CSF) levels of Aβ were associated with white matter lesions, cerebral microbleeds, hypertension, diabetes and ischemic heart disease. In summary, plasma Aβ is overtly decreased during the dementia stage of AD indicating that prominent changes in Aβ metabolism occur later in the periphery compared to the brain. Further, increased levels of Aβ in plasma are associated with vascular disease.

Indexed as

AgedAlzheimer DiseaseAmyloid beta-PeptidesApolipoprotein E4BiomarkersCohort StudiesFemaleHumansMaleNeocortexPositron-Emission TomographyVascular DiseasesAmyloid beta-PeptidesApolipoprotein E4Biomarkers

Identifiers

PMID27241045
PMCPMC4886210
OpenAlexW2414917913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.